Drug Profile
Zoligratinib - Debiopharm
Alternative Names: CH 5183284; DEBIO-1347; Debio1347; FF 284Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Debiopharm
- Class Amines; Antineoplastics; Benzimidazoles; Indoles; Ketones; Pyrazoles; Small molecules
- Mechanism of Action Signal transduction pathway inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Breast cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Singapore (PO)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in South Korea (PO)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Spain (PO)